Literature DB >> 25820779

RORγt(+) hematopoietic cells are necessary for tumor cell proliferation during colitis-associated tumorigenesis in mice.

Maria Martin1, Rebecca K Kesselring1, Balam Saidou1, Stefan M Brunner1, Gabriela Schiechl1, Verena F Mouris1, Anja K Wege2, Petra Rümmele3, Hans J Schlitt1, Edward K Geissler1, Stefan Fichtner-Feigl1,4.   

Abstract

Colorectal cancer (CRC) is one of the most common tumor entities. In patients with inflammatory bowel diseases, the development of colitis-associated colon cancer is considered a dangerous long-term complication. IL-17A and the transcription factor retinoic acid receptor-related orphan receptor γt (RORγt) play fundamental roles in the pathogenesis of inflammatory bowel diseases; in human studies, we detected a dense infiltration of RORγt-dependent CD4(+) IL17A(+) T helper (Th)17 cells in specimens of CRC, ulcerative colitis, and ulcerative colitis-associated colorectal cancer. However, the mechanistic role of RORγt(+) hematopoietic cells in colitis-associated tumorigenesis remains unclear. To investigate colitis-associated colon tumorigenesis, we conducted studies in the AOM+DSS mouse model that revealed the importance of RORγt for colon tumor progression. In the absence of RORγt-dependent Th17 lymphocytes, mice showed signs of intense chronic colitis, but developed significantly fewer macroscopic tumor nodules. The reduction of tumor development in RORγt(-/-) mice was not due to reduced colon tumor initiation. However, the proliferation rate of tumor cells was reduced in the absence of RORγt-dependent Th17 cells and tumor cells showed pronounced signs of senescence-associated epigenetic and lysosomal changes. These results indicate an important role for the immunological milieu in colitis-associated cancer, which is shaped in-part by RORγt-dependent Th17 lymphocytes that support CRC growth.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  AOM+DSS; Colitis-associated colorectal cancer; IL-17; RORγt; Th17 cells

Mesh:

Substances:

Year:  2015        PMID: 25820779     DOI: 10.1002/eji.201444915

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells.

Authors:  Caroline Theresa Seebauer; Stefan Brunner; Gabriel Glockzin; Pompiliu Piso; Petra Ruemmele; Hans-Juergen Schlitt; Edward Kenneth Geissler; Stefan Fichtner-Feigl; Rebecca Kesselring
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110

2.  VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease.

Authors:  Leo R Fitzpatrick; Jeff Small; Robert O'Connell; George Talbott; Gordon Alton; Jim Zapf
Journal:  Inflammopharmacology       Date:  2019-09-23       Impact factor: 4.473

3.  Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer.

Authors:  Renuka Subramaniam; Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  Cancer Res Front       Date:  2016-01-21

4.  Astragalus polysaccharide attenuates rat experimental colitis by inducing regulatory T cells in intestinal Peyer's patches.

Authors:  Hai-Mei Zhao; Yan Wang; Xiao-Ying Huang; Min-Fang Huang; Rong Xu; Hai-Yang Yue; Bu-Gao Zhou; Hong-Yan Huang; Qi-Meng Sun; Duan-Yong Liu
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

5.  The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.

Authors:  Vy Phan-Lai; Yushe Dang; Ekram Gad; Jennifer Childs; Mary L Disis
Journal:  Clin Cancer Res       Date:  2015-12-09       Impact factor: 12.531

6.  Immune translational control by CPEB4 regulates intestinal inflammation resolution and colorectal cancer development.

Authors:  Annarita Sibilio; Clara Suñer; Marcos Fernández-Alfara; Judit Martín; Antonio Berenguer; Alexandre Calon; Veronica Chanes; Alba Millanes-Romero; Gonzalo Fernández-Miranda; Eduard Batlle; Mercedes Fernández; Raúl Méndez
Journal:  iScience       Date:  2022-01-22

7.  Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy.

Authors:  Monika Bilska; Anna Pawłowska; Ewelina Zakrzewska; Agata Chudzik; Dorota Suszczyk; Marek Gogacz; Iwona Wertel
Journal:  J Oncol       Date:  2020-02-21       Impact factor: 4.375

8.  Immune and microRNA responses to Helicobacter muridarum infection and indole-3-carbinol during colitis.

Authors:  Rasha Raheem Alkarkoushi; Yvonne Hui; Abbas S Tavakoli; Udai Singh; Prakash Nagarkatti; Mitzi Nagarkatti; Ioulia Chatzistamou; Marpe Bam; Traci L Testerman
Journal:  World J Gastroenterol       Date:  2020-08-28       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.